Literature DB >> 24342984

Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE.

David A Isenberg1, Anisur Rahman1.   

Abstract

Clinical, basic and translational research in systemic lupus erythematosus are fast-moving fields. 2013 has seen the publication of some potentially landmark papers, which not only explore the potential of novel agents but also glean new insights from past trials.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24342984     DOI： 10.1038/nrrheum.2013.203

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus.

Authors:  P Rahman; D D Gladman; M B Urowitz; D Hallett; L S Tam
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Authors:  Marie B Condon; Damien Ashby; Ruth J Pepper; H Terence Cook; Jeremy B Levy; Megan Griffith; Tom D Cairns; Liz Lightstone
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

3.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

4.  Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

Authors:  Amara N Ezeonyeji; David A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2011-11-16       Impact factor: 7.580

5.  Damage in lupus patients--what have we learned so far?

Authors:  L Eder; M B Urowitz; D D Gladman
Journal:  Lupus       Date:  2013-10       Impact factor: 2.911

6.  Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.

Authors:  David Wofsy; Jan L Hillson; Betty Diamond
Journal:  Arthritis Rheum       Date:  2013-06

7.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01

8.  Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells.

Authors:  Anneleen Bosma; Azza Abdel-Gadir; David A Isenberg; Elizabeth C Jury; Claudia Mauri
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

9.  Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis.

Authors:  Ngianga-Bakwin Kandala; Martin Connock; Amy Grove; Paul Sutcliffe; Syed Mohiuddin; Louise Hartley; Rachel Court; Ewen Cummins; Caroline Gordon; Aileen Clarke
Journal:  BMJ Open       Date:  2013-07-19       Impact factor: 2.692

10.  Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Authors:  Daniel J Wallace; Kenneth Kalunian; Michelle A Petri; Vibeke Strand; Frederic A Houssiau; Marilyn Pike; Brian Kilgallen; Sabine Bongardt; Anna Barry; Lexy Kelley; Caroline Gordon
Journal:  Ann Rheum Dis       Date:  2013-01-12       Impact factor: 19.103
  10 in total
  5 in total

Review 1.  Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.

Authors:  Thomas Dörner; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

Review 2.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

Review 3.  [Basophilic granulocytes and autoimmune diseases. Can basophilic granulocytes modulate B-cell functions in systemic lupus erythematosus?].

Authors:  A Meyer-Bahlburg; D Dijkstra
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

4.  Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Authors:  Karina A de Groot; Michel Tsang A Sjoe; Denise Niewerth; Jacqueline Cloos; Jonathan L Blank; Hans W M Niessen; Sonja Zweegman; Alexandre E Voskuyl; Gerrit Jansen; Joost W van der Heijden
Journal:  Lupus Sci Med       Date:  2015-12-18

5.  Lupus nephritis in children - 10 years' experience.

Authors:  Hanna Szymanik-Grzelak; Elżbieta Kuźma-Mroczkowska; Jadwiga Małdyk; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2016-10-25       Impact factor: 2.085
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.